N4 Pharma PLC’s (AIM: N4P) shares have risen by more than 7% following the biotech firm’s announcement that it has successfully completed the single loading of EGFR and BCL-2 siRNA nucleotides onto Nuvec.
Nuvec is N4 Pharma’s innovative delivery system for cancer treatments and vaccines, and the firm has achieved good monodisperse formulations.
N4 Pharma has reported that the EGFR siRNA, which was single-loaded, has demonstrated significant silencing of the EGFR gene. Furthermore, a strong dose-response curve has been established, allowing the company to identify the dosage it can use in the in-vivo study.
The next phase for EGFR involves measuring cell apoptosis to demonstrate a meaningful in vitro clinical effect, according to the company.
Nigel Theobald, N4 Pharma’s CEO, said the results were excellent, showcasing the effective knockdown of the siRNA and the clear dose-response curve. He added that this is evidence of how well-suited Nuvec is for working with siRNA.
As of early morning trading, N4 Pharma’s shares had risen by 7.7%, or 0.15p, to 2.10p.
